处于小细胞肺癌免疫治疗新一代生物标志物的前沿。 - Suppr

Suppr

超能文献

On the precipice of a new generation of biomarkers for immunotherapy in small cell lung cancer.

作者信息

Sun Peiran, Snow Stephanie

机构信息

Division of Medical Oncology, Department of Internal Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.

QEII Health Sciences Centre, Halifax, Nova Scotia, Canada.

出版信息

Transl Cancer Res. 2025 Jan 31;14(1):24-28. doi: 10.21037/tcr-24-1711. Epub 2025 Jan 23.

DOI:10.21037/tcr-24-1711

PMID:39974403

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11833411/

Abstract

摘要

相似文献

On the precipice of a new generation of biomarkers for immunotherapy in small cell lung cancer.处于小细胞肺癌免疫治疗新一代生物标志物的前沿。

Transl Cancer Res. 2025 Jan 31;14(1):24-28. doi: 10.21037/tcr-24-1711. Epub 2025 Jan 23.

Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.综合基因组分析、肿瘤突变负担和 PD-L1 表达的整合，以鉴定非小细胞肺癌免疫治疗的新型生物标志物。

Cancer Med. 2021 Apr;10(7):2216-2231. doi: 10.1002/cam4.3649. Epub 2021 Mar 2.

Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。

JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.

Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.通过靶向测序进行基因组评分，以确定免疫治疗的临床获益。

Eur J Cancer. 2019 Oct;120:65-74. doi: 10.1016/j.ejca.2019.08.001. Epub 2019 Sep 4.

Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer.肿瘤突变负担作为晚期非小细胞肺癌中 PD-1/PD-L1 抑制的潜在生物标志物。

Target Oncol. 2020 Feb;15(1):93-100. doi: 10.1007/s11523-020-00703-3.

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.非小细胞肺癌中高肿瘤突变负荷与 PD-L1 表达水平相关的免疫浸润增加和 PD-L1 阻断临床获益改善的相关性。

JAMA Oncol. 2022 Aug 1;8(8):1160-1168. doi: 10.1001/jamaoncol.2022.1981.

Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy.探索基于全基因组测序的生物标志物在无法接受靶向治疗的晚期肺癌患者中进行治疗选择的成本效益。

Pharmacoeconomics. 2024 Apr;42(4):419-434. doi: 10.1007/s40273-023-01344-w. Epub 2024 Jan 9.

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.利用下一代测序癌症基因 panel 评估血液肿瘤突变负担作为非小细胞肺癌患者免疫治疗的潜在生物标志物。

JAMA Oncol. 2019 May 1;5(5):696-702. doi: 10.1001/jamaoncol.2018.7098.

A narrative review of current and potential prognostic biomarkers for immunotherapy in small-cell lung cancer.小细胞肺癌免疫治疗的当前及潜在预后生物标志物的叙述性综述。

Ann Transl Med. 2021 May;9(9):809. doi: 10.21037/atm-21-68.

Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.抗程序性死亡配体1（PD-L1）免疫检查点抑制剂联合依托泊苷和铂类治疗广泛期小细胞肺癌：一例病例报告

Ann Palliat Med. 2021 Jan;10(1):828-835. doi: 10.21037/apm-20-2574.

引用本文的文献

Prognostic factors of liver metastases in extensive-stage small cell lung cancer receiving chemo-immunotherapy.接受化疗免疫治疗的广泛期小细胞肺癌肝转移的预后因素

Transl Lung Cancer Res. 2025 May 30;14(5):1569-1581. doi: 10.21037/tlcr-2024-1091. Epub 2025 May 28.

本文引用的文献

Clin Oncol (R Coll Radiol). 2024 Oct;36(10):e408-e419. doi: 10.1016/j.clon.2024.06.056. Epub 2024 Jul 2.

Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.广泛期小细胞肺癌免疫治疗的分子分类和预后标志物：CASPIAN 三期研究分析。

Mol Cancer. 2024 May 30;23(1):115. doi: 10.1186/s12943-024-02014-x.

Uncommon Adverse Events of Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Systematic Review of Case Reports.小细胞肺癌中免疫检查点抑制剂的罕见不良事件：病例报告的系统评价

Cancers (Basel). 2024 May 16;16(10):1896. doi: 10.3390/cancers16101896.

Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.小细胞肺癌中的免疫异质性和对免疫检查点阻断的易感性。

Cancer Cell. 2024 Mar 11;42(3):429-443.e4. doi: 10.1016/j.ccell.2024.01.010. Epub 2024 Feb 15.

Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients.广泛期小细胞肺癌患者免疫治疗获益的组织和循环生物标志物。

Front Immunol. 2024 Jan 29;15:1308109. doi: 10.3389/fimmu.2024.1308109. eCollection 2024.

Prognostic biomarkers and immune cell infiltration characteristics in small cell lung cancer.小细胞肺癌的预后生物标志物及免疫细胞浸润特征

Cancer Pathog Ther. 2022 Oct 17;1(1):18-24. doi: 10.1016/j.cpt.2022.09.004. eCollection 2023 Jan.

Targeting DHX9 Triggers Tumor-Intrinsic Interferon Response and Replication Stress in Small Cell Lung Cancer.靶向 DHX9 可触发小细胞肺癌中的肿瘤内在干扰素反应和复制应激。

Cancer Discov. 2024 Mar 1;14(3):468-491. doi: 10.1158/2159-8290.CD-23-0486.

Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies.小细胞肺癌的蛋白质基因组学特征分析为其提供了生物学见解和亚型特异性的治疗策略。

Cell. 2024 Jan 4;187(1):184-203.e28. doi: 10.1016/j.cell.2023.12.004.

Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.度伐利尤单抗 ± 替西木单抗联合铂类依托泊苷治疗广泛期小细胞肺癌（CASPIAN）：基于 PD-L1 表达和组织肿瘤突变负荷的结果。

Clin Cancer Res. 2024 Feb 16;30(4):824-835. doi: 10.1158/1078-0432.CCR-23-1689.

Immunotherapy-related biomarkers: Confirmations and uncertainties.免疫治疗相关生物标志物：确认与不确定性。

Crit Rev Oncol Hematol. 2023 Dec;192:104135. doi: 10.1016/j.critrevonc.2023.104135. Epub 2023 Sep 17.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验